Antipeptide antibodies define the NH2-terminal structure of the pan-specific hemopoietin interleukin 3
- PMID: 2433341
Antipeptide antibodies define the NH2-terminal structure of the pan-specific hemopoietin interleukin 3
Abstract
Antipeptide antibodies were raised in rabbits against a synthetic peptide including the six NH2-terminal amino acids of the pan-specific hemopoietin interleukin 3 (IL 3). Affinity-purified antibody preparations specific for epitopes determined by residues 1 to 6 were immobilized and used as affinity columns. Up to 98% of IL 3 bioactivity in T cell-conditioned medium was depleted by these columns, as was 71 and 74%, respectively, of IL 3 aberrantly produced by the myeloid leukemias WEHI-274.14 and WEHI-3B. IL 3 produced in vivo in WEHI-3B tumor-bearing mice also bound to the anti-1-6 antibody column, up to 70% of the bioactivity being depleted from ascites fluid and up to 84% from the serum. These results suggest that all IL 3 secreted by T cells and the majority of the IL 3 molecules secreted by myeloid leukemias express epitopes determined by residues 1-6 and cannot have the NH2-terminal amino acid sequence initially reported for IL 3. These six NH2-terminal amino acids share similarities with the NH2-terminal amino acids of several other lymphokines, suggesting an important function for this hexapeptide.
Similar articles
-
Antipeptide antibodies of predetermined specificity recognize and neutralize the bioactivity of the pan-specific hemopoietin interleukin 3.J Immunol. 1987 Feb 15;138(4):1099-104. J Immunol. 1987. PMID: 2433340
-
Monoclonal antipeptide antibodies recognize IL-3 and neutralize its bioactivity in vivo.J Immunol. 1988 Feb 15;140(4):1182-7. J Immunol. 1988. PMID: 3257773
-
Neutralizing monoclonal antibodies to human IL-8 receptor A map to the NH2-terminal region of the receptor.J Immunol. 1994 Feb 15;152(4):1783-9. J Immunol. 1994. PMID: 8120387
-
Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.J Mol Recognit. 1993 Jun;6(2):81-94. doi: 10.1002/jmr.300060206. J Mol Recognit. 1993. PMID: 7508238
-
Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics.J Immunol. 1983 Oct;131(4):1808-15. J Immunol. 1983. PMID: 6352804
Cited by
-
Role of disulfide bridges in determining the biological activity of interleukin 3.Proc Natl Acad Sci U S A. 1988 Nov;85(21):7897-901. doi: 10.1073/pnas.85.21.7897. Proc Natl Acad Sci U S A. 1988. PMID: 3263644 Free PMC article.
-
Structure-function relationships of interleukin-3. An analysis based on the function and binding characteristics of a series of interspecies chimera of gibbon and murine interleukin-3.J Clin Invest. 1992 Nov;90(5):1879-88. doi: 10.1172/JCI116065. J Clin Invest. 1992. PMID: 1385477 Free PMC article.
-
Mechanism of autocrine stimulation in hematopoietic cells producing interleukin-3 after retrovirus-mediated gene transfer.Mol Cell Biol. 1989 Jan;9(1):204-13. doi: 10.1128/mcb.9.1.204-213.1989. Mol Cell Biol. 1989. PMID: 2467186 Free PMC article.
-
Growth factor gene activation and clonal heterogeneity in an autostimulatory myeloid leukemia.Mol Cell Biol. 1989 Jun;9(6):2414-23. doi: 10.1128/mcb.9.6.2414-2423.1989. Mol Cell Biol. 1989. PMID: 2668733 Free PMC article.